Jasper Therapeutics, Inc. JSPR

JSPR Company Overview

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted conditioning therapies for hematopoietic stem cell transplantation (HSCT), gene therapy, and treatment of chronic autoimmune diseases. The company operates within the biotechnology and biopharmaceutical industries, with a primary emphasis on antibody-based therapeutics designed to selectively deplete stem cells and immune cells while reducing the toxicities associated with traditional conditioning regimens such as chemotherapy and radiation. Its lead product candidate, briquilimab (formerly JSP191), is an anti-CD117 monoclonal antibody intended for use across multiple disease settings.

The company’s principal revenue driver has historically been collaboration and licensing activity rather than commercial product sales, as it remains in the clinical development stage. Jasper Therapeutics primarily serves healthcare providers, transplant centers, gene therapy developers, and patients with rare diseases and immune-mediated conditions. The company’s strategic positioning is based on the potential for targeted conditioning approaches to improve transplant outcomes and expand eligibility for stem cell and gene therapies. Jasper Therapeutics was founded in 2018 and became publicly traded through a merger with a special purpose acquisition company in 2021, after which it expanded clinical development efforts around briquilimab and related therapeutic applications.